April — May 2026
Investor Update
Dear Investors, we are pleased to share several updates from April and May, including continued progress in U.S. commercial activity, fundraising, regulatory strategy, and clinical expansion.
Highlights
Completed a pilot at North Shore University Hospital, part of Northwell Health
Continued progress toward a priced financing round, including the addition of a new investor
Submitted a Breakthrough Device Designation application to the FDA
Advanced U.S. hospital pilots and implementation planning
Submitted a $600K grant application to support new R&D efforts
Fundraising Activities
- We are honoured to welcome Dan Doctoroff, former CEO of Bloomberg LP, as a new investor in EyeControl.
- Or Retzkin, EyeControl's CEO, recently visited the U.S. to meet with investors and key stakeholders, supporting continued progress toward the priced round. We are currently in various stages of discussion with several investors, including a list of investors awaiting a term sheet.
Non-Dilutive Funding
We recently submitted an application for a grant from the Israel Innovation Authority to support new R&D efforts.
Commercial Activities
- We recently completed a five-week pilot at North Shore University Hospital, part of Northwell Health. The pilot included three hospital units and represents an important step in our broader work with the Northwell system.
- Later this month, we expect to begin an implementation in three units at Long Island Jewish Medical Center, also part of Northwell Health. The implementation will be supported jointly by hospital funding and a grant from the Israel Ministry of Finance. Together with our signed master agreement with Northwell Health, this marks meaningful progress in expanding our activity within the largest healthcare system in New York.
- Training and setup have also begun for a several-month pilot at Strong Memorial Hospital, part of the University of Rochester, alongside our reseller partner, TPC Systems.
- In parallel, we are in advanced stages of hiring our first dedicated U.S.-based employee to oversee commercial implementations and support our growing U.S. hospital activity.
- We have initiated early engagement with the U.S. Department of Veterans Affairs to support potential implementation in VA hospitals.
- During his U.S. trip, Or also met with stakeholders at SciTech Scity, New Jersey's government-supported innovation hub, to explore commercial and funding opportunities within the state.
Regulatory
We submitted a Breakthrough Device Designation application to the FDA for EyeControl as a delirium management solution.
Strategic Partnerships
- We continue to hold discussions with strategic partners regarding potential collaboration opportunities.
- In June, EyeControl will participate in the American Delirium Society meeting in Denver.
Financials
B&R increased as a result of changes in the USD/NIS exchange rate.
Intellectual Property
We recently received a new patent that further strengthens protection around EyeControl's core technology platform.